IDH1 and diffuse astrocytoma: Noteworthy, patients with diffuse astrocytomas without IDH mutations are at substantial risk of a worse course of the disease [7], which might be interpreted as an argument in favor of an HGG-like treatment, even in the absence of high-risk clinical features [6].